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Purpose: The overexpression of ATP-binding cassette transporters (ABC transporters), mainly 
including permeability glycoproteins (P-gp), multidrug resistance (MDR)-related protein 1 
(MRP1), and breast cancer resistance proteins (BCRP), is one of the main reasons for the 
development of MDR which directly leads to chemotherapy failure. However, most of the cur-
rently used detection methods in MDR-related studies are qualitative or semiquantitative, but 
not quantitative. As a result, the measurement criteria of different experiments are not unified. 
Moreover, there are many contradictory results of the studies of the induction effect of drugs 
on ABC transporters. So, it is necessary to establish a quantitative assay for the quantification 
of P-gp, MRP1, and BCRP to study the mechanism of drug resistance.
Methods: In this paper, a novel and advanced liquid chromatography/mass spectrometry (MS)/
MS-based targeted proteomics method for the quantification of P-gp, MRP1, and BCRP was 
developed and validated. Then, the cell lines MCF-7, HepG-2, and SMMC-7721 were, respec-
tively, induced by different concentrations of doxorubicin (adriamycin [ADM]), mitoxantrone 
(MX), and methotrexate (MTX), to establish resistance cell lines. The method established was 
used to quantify the expression of P-gp, MRP1, and BCRP.
Results: The result showed that the induction effects of drugs on protein were relatively stable 
and selective. ADM, MX, and MTX could induce overexpression of P-gp, MRP1, and BCRP. 
And, the induction effect of different drugs on proteins was selective. The pattern of overexpres-
sion of ABC transporters in the three types of resistance cell lines was different. 
Conclusion: During the development of drug resistance, the cell type and patch, but not drug 
type, were the most important determinant factors of the overexpression level of ABC trans-
porters in resistance cell lines. This study provides a good foundation for understanding the 
development of drug resistance in cell lines and can be used to explain the contradictory results 
in other published studies as described above.
Keywords: P-gp, MRP1, BCRP, multidrug resistance, quantification 
Introduction
The development of multidrug resistance (MDR) remains a major clinical obstacle in 
current cancer therapy, which is the main cause of chemotherapy failure.1
The mechanism of MDR is complicated. One of the determinant factors is the ini-
tiative efflux of drugs across the cell membrane via ATP-binding cassette transporter 
(ABC transporter).2 ABC transporters mainly include permeability glycoprotein (P-gp), 
MDR-related protein 1 (MRP1), and breast cancer resistance proteins (BCRP). Many 
chemotherapeutic agents are substrates of ABC transporters, which are pumped out 
of cells and as a result their intracellular accumulation is reduced.3 It has been found 
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that, when tumor cells exposed to a cytotoxic agent induce 
cross-resistance, ABC transporter expression moves from 
higher expressing cells to the cells that have low expression 
of the corresponding protein in a wave and stepwise man-
ner. Consequently, the sensitive cells with low expression 
of drug transporter turn into resistant ones.4,5 To solve this 
clinical problem, the induction effects of drugs on protein 
and the inhibitor of ABC transporter have been extensively 
studied.6–10
To induce drug resistance, cells are treated with the drug 
until they become resistant, and then protein expression in 
the resistance cell line is detected and compared with that 
in the parental cell line.7,9,11–17 However, there are many 
contradictory results from different studies that cannot be 
explained. For example, in the studies of the induction effects 
of adriamycin (ADM) on MRP1 (short-term drug exposure), 
Louisa et al7 proved that the resistance of MCF-7/ADM is 
closely related to the overexpression of MRP1, while Yan et 
al15 claimed that the MRP1 expression in HepG-2/ADM and 
SMMC-7721/ADM was not significantly higher than that in 
the parental cells. Different types of cell lines used in the two 
experiments may explain the contradictory results. However, 
Zhai et al18 showed that MRP1 was overexpressed in HepG-2/
ADM, using the same type of cell line as Yan et al but with 
a contrary conclusion.
Assumptions to these phenomena are explained as fol-
lows. 1) The determinant of whether the drug can induce 
drug resistance of cells is the cell’s type. The drug is the less 
important contributor. 2) The methods used are qualitative 
or semiquantitative which are not precise enough to observe 
minor differences caused by the drug. Meanwhile, the clini-
cal results were disappointing because of the lack of proper 
analysis techniques to monitor the accurate level of ABC 
transporters.19,20 So, it is necessary to establish a quantitative 
assay for the quantification of P-gp, MRP1, and BCRP to 
study the pattern of ABC transporters overexpression in the 
development of drug resistance in different types of cell lines.
Quantitative targeted absolute proteomics (QTAP) is 
a new technology based on biological mass spectrometry 
(MS), which demonstrates remarkable abilities of separat-
ing and measuring the target protein from the biological 
matrix.21 Amino acid sequence-dependent mass transitions 
of protein-specific peptides (surrogate peptide) generated 
by tryptic digestion are monitored for quantification.22 The 
multiple reaction monitoring mode (MRM) of MS can be 
used to filter the parent and fragments ions; so surrogate 
peptide can be detected from biological samples to quantify 
the target protein.
In this paper, a novel and advanced liquid chromatogra-
phy (LC)/MS/MS-based QTAP assay for the quantification 
of P-gp, MRP1, and BCRP was developed and validated. 
Different concentrations of ADM, mitoxantrone (MX), 
and methotrexate (MTX) were used to induce the cell lines 
MCF-7, HepG-2, and SMMC-7721 to establish resistance 
cell lines. Then, the assay was applied to comprehensively 
analyze the expression of the ABC transporters in these 
resistance cell lines, and the corresponding gene expression 
was determined using real-time polymerase chain reaction 
(RT-PCR) to evaluate the consistency between mRNA and 
protein expression.
Materials and methods
Chemicals and reagents
MCF-7, HepG-2, and SMMC-7721 cell lines were all pur-
chased from the Cell Bank of Chinese Academy of Sciences 
(Beijing, China). The protein quantification bicinchoninic 
acid (BCA) kit was purchased from Pierce Biotechnology 
(Rockford, IL, USA). Sequencing grade modified trypsin was 
purchased from Merck & Co, Inc (Whitehouse Station, NJ, 
USA). HPLC-grade acetonitrile and methanol were purchased 
from EMD Millipore (Billerica, MA, USA). The peptides 
and the stable isotope-labeled internal standards (IS) were 
obtained from Jill Biochemical Co (Shanghai, China). Human 
serum albumin (HSA) was obtained from Sigma-Aldrich 
(St Louis, MO, USA). Ammonium bicarbonate (NH
4
HCO
3
) 
was obtained from Qiangshun Chemical Reagent Co, Ltd 
(Shanghai, China). Dithiothreitol (DTT) was obtained from 
Amersco (Cleveland, OH, USA). Iodoacetamide (IAA), 
Tris/HCl, trifluoroacetic acid (TFA), and Triton X-114 were 
supplied by Sigma-Aldrich. Phosphate-buffered saline was 
purchased from the Beyotime Institute of Biotechnology 
(Jiangsu, China). Water was purified and deionized with a 
Milli-Q system manufactured by Merck Millipore (Billerica, 
MA, USA). Dulbecco’s modified Eagle’s medium (DMEM), 
RPMI-1640, and trypsin containing 0.25% EDTA were 
obtained from Thermo Fisher Scientific (Waltham, MA, 
USA). Fetal bovine serum and Trizol were also obtained from 
Thermo Fisher Scientific. Drugs ADM (CAS: 25316-40-9; 
Machlia, Shanghai, China), MTX (CAS: 59-05-2), and MX 
(CAS: 70476-82-3, ID: F818-ZHFX) were obtained from 
National Institutes for Food and Drug Control, China. 
Identification of surrogate peptides and 
optimal MRMs
Surrogate peptides for P-gp, MRP1, and BCRP were deter-
mined using a combined approach of in silico predictions 
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and experimental data. Briefly, a full protein sequence was 
obtained from National Center for Biotechnology Informa-
tion (NCBI), and then a list of potential peptides was gener-
ated by using in silico digestion tools: UniProt (the regions of 
uncertainty and instability excluded) and Skyline (to predict 
peptides that the target protein digested and the MS informa-
tion of every peptide). Protein specificity of each observed 
peptide was assured by NCBI protein Basic Local Align-
ment Search Tool search against the UniProtKB/Swiss-Prot 
database. Moreover, these peptides had to meet the follow-
ing criteria. 1) Their mass range should to be detectable in 
triple quadrupole MS; only peptides with 7–22 amino acids 
can be selected. 2) Continuous sequence of arginine (R) or 
lysine (K) (eg, RR, KK, RK, or KR) (ragged ends) should 
be excluded as it may cause incomplete trypsin digestion. 3) 
The best proportion of hydrophobic amino acids is 25%–50% 
so as to ensure that the peptide selected can be completely 
dissolved in water.
In parallel, a Waters ACQUITY ultra performance liquid 
chromatography (UPLC) system consisting of a triple quad-
rupole mass spectrometer (UPLC-XEVO TQ-S MS; Waters 
Corporation, Milford, MA, USA) equipped with a sample 
management system (IntelliStart; Waters Corporation) was 
used to verify the appropriate specific peptide candidates. A 
programmable column management system (Waters Cor-
poration) was used for sample analysis. In order to create 
optimal multiple reaction monitoring (MRM) methods for 
the best observed peptides, appropriate mass transitions for 
each peptide were identified and optimized by manual infu-
sion of synthetic peptides and their stable isotope-labeled 
counterparts. For each peptide, the mass transitions of highest 
intensity were chosen.
LC–MS/MS analysis 
The Waters ACQUITY UPLC system described above was 
used for sample analysis. The LC separations were performed 
on an ACQUITY UPLC BEH C18 column (2.1×50 mm, 1.7 
μm; Waters Corporation) at 35°C. The mobile phase consisted 
of solvent A (0.1% formic acid in water) and solvent B (0.1% 
formic acid in methanol). A linear gradient with a flow rate 
of 0.5 mL/min was applied in the following manner: 2% B (5 
minutes) → 2%–25% B (10 minutes) → 25% B (1 minute) 
→ 45% B (2 minutes). The injection volume was 5 μL.
The mass spectrometer was equipped with electrospray 
ionization and operated in the positive ion mode to monitor 
the m/z transitions for all peptides and the corresponding IS 
peptides given in Table 1. The scheduled MRM acquisition 
method was constructed using manually optimized mass 
spectrometer source parameters: 1000 L/h desolvation gas 
flow, 3 kV spray voltage, and 350°C source temperature. Data 
were processed by integrating the appropriate peak areas 
from the reconstructed ion chromatograms for the 9-mer 
analytic peptides and the SIL-IS peptide using the Analyst 
1.8.2 software (UNIFI Scientific Information System; Waters 
Corporation). 
Preparation of calibration curves, method 
validation
For preparation of calibration curves, digested HSA (digested 
as described below) was used as the blank matrix and was 
spiked with increasing amounts of chosen peptides. The 
calibration standards concentrations were 0.1, 0.2, 0.5, 1.0, 
2.0, 5.0, 10, 20, 50, and 100 ng/mL. The standard quality 
control (QC) solutions for the lower limit of quantification 
(LLOQ), low QC, mid QC, and high QC were 0.1, 0.16, 4, 
and 80 ng/mL, respectively. The stock solution was diluted 
with water:acetonitrile (ACN) mixture (50:50, V/V) to pre-
pare an IS solution (30 ng/mL).
Method validation involved detecting several key param-
eters to establish credibility in assay performance, linearity, 
LLOQ, accuracy and precision, and the blank matrix effect 
as well as stability. Sample analysis was conducted according 
to current regulatory guidelines for macromolecular proteins. 
A double blank without any peptides and a zero standard 
Table 1 Details of mass transitions of m/z and mass spectrometry conditions
Protein Peptide Mass transition Fragmentation  
voltage (V)
Collision  
energy (eV)
P-gp IATEAIENFR 582.3→749.5 20 25
IATEAIENFR 585.75→756.2 20 25
MRP1 EDAQVDLFR 546.7→649.3 25 17
EDAQVDLFR 550.3→ 656.1 25 17
BCRP SSLLDVLAAR 522.8→644.4 20 20
SSLLDVLAAR 526.3→651.1 20 20
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins.
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containing IS peptides were analyzed in duplicate for the 
calibration curve. QC samples which spiked with analytic 
peptide to specific final concentrations in normal human 
serum were tested in five replicates.
Stability was evaluated by analyzing QC samples (0.16, 
4, and 80 ng/mL) exposed to different conditions: at room 
temperature for 6 hours before sample preparation, and at 
room temperature for 16 hours after sample preparation. Pep-
tide stability during overnight tryptic digestion was studied 
by measuring the prepared samples immediately before and 
after incubation for 16 hours at 37°C.
The protein digestion efficiency was determined by 
using a membrane protein processed as described which 
was digested for 2, 4, 16, and 24 hours at 37°C. In each case, 
200 μg membrane protein was digested in triplicate and the 
peptide concentration was detected for P-gp, MRP1, and 
BCRP as these transporters are known to be expressed in 
drug-resistant cell lines. The concentrations of target pro-
teins under different times of digestion were divided by that 
digested for 16 hours to calculate the digestion efficiency.
Development of resistance cell lines and 
membrane protein extraction
The MTT method was used to measure the half maximal 
inhibitory concentration values (IC
50
) of ADM, MX, and 
MTX on each cell line, and the average of IC
50
 was used 
as the initial induction concentration of each drug: ADM is 
0.168 μg/mL, MX is 0.209 μg/mL, and MTX is 0.319 μg/mL. 
Cell lines MCF-7 and HepG-2 were maintained in DMEM 
media and SMMC-7721 was cultured in RPMI-1640 media, 
all supplemented with 10% FBS, 100 units penicillin, and 
100 μg/mL streptomycin at 37°C and 5% CO
2
. Cell lines 
MCF-7, HepG-2, and SMMC-7721 were induced by differ-
ent concentrations of ADM, MX, and MTX, respectively, to 
establish resistance cell lines (MCF-7/ADM, MCF-7/MX, 
MCF-7/MTX, HepG-2/ADM, HepG-2/MX, HepG-2/MTX, 
SMMC-7721/ADM, SMMC-7721/MX, and SMMC-7721/
MTX). The parental cell lines were induced by drugs under 
1/10 of the initial induction concentrations, and then the 
concentrations were gradually increased. After 7–9 passages 
(21–27 days), the parental cells developed drug resistance. 
After that, the concentration of the drug was increased until 
the cell lines could grow steadily at concentrations of 1, 2, 
and 3 times of the initial concentration.
Cells whose numbers were diluted to 106–107 were pel-
leted at 1500×g for 10 minutes, and then suspended in 500 
μL of 1% Triton X-114 extraction buffer (1 mM DTT, 2 mM 
EDTA in 50 mM Tris/HCl, pH 7.4) containing a protease 
inhibitor cocktail. The samples were incubated on ice for 30 
minutes with a 1–2 minute shake in every 10 minutes, and 
then incubated for 10 minutes at 37°C. For separating the 
detergent and aqueous phases, the samples were centrifuged 
at 10,000×g for 10 minutes. Then, 500 μL of the 1% Triton 
X-114 extraction buffer and 500 μL of 0.06% Triton X-114 
wash buffer (1 mM DTT, 2 mM EDTA in 50 mM Tris/HCl, 
pH 7.4) were added into the aqueous phase and the detergent 
phase, respectively. For achieving complete extraction, the 
incubation and centrifugation steps were repeated. Then, the 
retained protein pellet was pooled and precipitated in cold 
acetone at −20°C for 1 hour. Finally, the protein pellet was 
resuspended in 1% SDS and stored at −80°C before analysis. 
Total isolated membrane protein concentration in the sample 
was determined using the BCA protein assay kit. 
Trypsin digestion
The concentration of the membrane fraction exacted was 
diluted to 2 mg/mL. Then, 100 μL of the cell membrane 
fraction was mixed with 50 μL of 50 mM NH
4
HCO
3
 buffer 
(pH 7.8). The mixture was vortexed for 2 minutes, reduced 
with 10 mM DTT at 60°C for 20 minutes. Then, the mixture 
was alkylated with 50 mM IAA in 50 mM ammonium and 
incubated at room temperature for 6 hours in the dark. After 
adding SIL-IS (30 ng/mL, 20 μL) and vortexing for 30 sec-
onds, the protein samples were digested by sequence-grade 
trypsin (trypsin:protein =1:20, w/w) at 37°C for 16 hours in 
the dark. Thereafter, 20 μL of 10% TFA was added to termi-
nate digestion. The final tryptic digestion was centrifuged 
at 16,000×g, 4°C for 15 minutes, and the supernatant was 
evaporated under a gentle stream of nitrogen at 45°C. The 
residue was dissolved by 100 μL of the mobile phase. After 
centrifugation at 16,000×g, at 4°C for 15 minutes, 5 μL of 
the supernatant was injected into the UPLC-MS/MS system. 
Following this, 100 μL solutions of each standard and QC 
were just subjected to tryptic digestion. 
Gene expression analysis
Total RNA from MCF-7, HepG-2, and SMMC-7721 cell 
lines and corresponding resistant cells were extracted by 
Trizol. An iQ5 RT-PCR, ABI 7500 instrument (Bio-Rad 
Laboratories Inc, Hercules, CA, USA) was used to carry 
out RT-PCR. The following primers were used: GAPDH 
(F), 5′-TGGGGAAACAGGGTAATGAG-3′; GAPDH 
(R), 5′-CTGGCCTTTGGTCTTTTTGA-3′; ABCB1 
(F), 5′-AACTTCCGAACCGTTGTTTC-3′; ABCB1 
(R), 5′-CCAAAGATGTGTGCTTTCCTC-3′; ABCC1 
(F), 5′-CTACCTCCTGTGGCTGAATC-3′; ABCC1 
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(R), 5′-ATCAGCTTGATCCGATTGTC-3′; ABCG2 (F), 
5′-ACAGGTGGAGGCAAATCTTC-3′; ABCG2 (R), 
5′-GCGGTGCTCCATTTATCAG-3′. Reactions were 
performed in triplicate for three biological replicates, and 
GAPDH mRNA levels were used for normalization. Melt-
curve analysis was performed to ensure that the mRNA-
specific fragments were amplified and the standard curve 
method was used for data analysis.
Statistical analysis
Statistical analysis was performed using SPSS for Windows 
version 22. (IBM Corporation, Armonk, NY, USA). Student’s 
t-test was used to compare two groups and Friedman M 
test was used to evaluate differences between three or more 
groups. The significance level P-value was set at 0.05.
Results and discussion
LC–MS/MS assay development and 
validation
LC–MS/MS analysis
To our knowledge, a validated method for quantification of 
P-gp, MRP1, and BCRP in resistance cell lines has not been 
developed so far. A prerequisite factor to achieve accurate 
quantification of proteins is the generation of high-quality 
MRM (multiple reaction monitoring).23 In order to create the 
best optimal MRM methods for detecting peptides, appropri-
ate mass transitions for each peptide were identified and opti-
mized by surrogate peptides and their stable isotope-labeled 
counterparts to a Waters TQ-S. Details of mass transitions of 
m/z and MS conditions are shown in Table 1. 
By using long gradient elution with a reverse phase col-
umn, chromatography was used to separate surrogate peptides 
from the complex biological matrix. A Waters ACQUITY 
UPLC system and a high flow rate of 0.5 mL/min were used to 
increase the chromatographic resolution. The first 5 minutes 
were directed to exclude hydrophilic compounds and salts. 
As there was no blank matrix for cell lines available, HSA 
was used as validation matrix to investigate the matrix effect. 
The resulting chromatograms for the method in digested HSA 
and samples are shown in Figure 1.
Method validation
There was a positive linear correlation between peptide con-
centration and the analytical signal for the entire validation 
range (0.1–100 nM) observed (1/x weighting) in each case. 
The correlation coefficients (r) for all calibration curves of all 
peptides (in each case N=10) were all >0.994 (P-gp: 0.997, 
MRP1: 0.998, BRCP: 0.994). The LLOQ of our analytical 
assays for P-gp, MRP1, and BCRP were all 0.1 nM, which 
is better than the LLOQ values from previously published 
LC–MS/MS methods.23–25
The precision and accuracy of the assay were assessed 
by observing the response of the QC samples with three 
different concentrations of each protein (0.16, 4, 80 ng/mL) 
in three validation runs (n=15). The intra and interday preci-
sions were expressed as the percent coefficient of variation. 
Accuracy was obtained by comparing the average calculated 
concentrations to their nominal values (%bias). Intraday as 
well as interday accuracies for all peptides in the validation 
matrix were within the required range of ±10% (±15% at 
LLOQ) and the precision was within the required range of 
±10% (±10% at LLOQ). The details are listed in Table 2.
Digestion efficiency 
To detect a surrogate peptide as an alternative to the target 
protein, insufficient digestion was a confounding interference 
to measurements. The protein digestion efficiency is shown 
in Figure 2. It can be observed that BCRP reached complete 
digestion after 16 hours while the digestion efficiency was 
nearly unchanged for MRP1. The different size and structure 
of proteins may be the reason that caused the difference in 
digestion efficiency. For P-gp, the digestion efficiency slowly 
decreased after 4 hours. However, the slippage between 4 
and 16 hours digestion was still within its digestion stabil-
ity (Table 3). As a compromise, the overnight digestion (16 
hours) procedure was used for intestinal samples to make 
sure of complete digestion.
Quantification of target proteins 
Expression levels of target proteins in parental cell 
lines
In order to determine whether ABC transporter overexpres-
sion in the development of MDR was affected by the cell 
type as assumed above, the target proteins concentrations in 
parental cell lines were firstly determined before induction. 
The result is shown in Figure 3. Friedman M test was used 
to analyze these data. It can be confirmed that the expression 
levels of the proteins in the three types of cell lines are dif-
ferent (P<0.05). The P-gp expression in SMMC-7721 and 
the MRP1 and BCRP expression in MCF-7 were higher than 
the others. The concentration of MRP1 in the three cell lines 
was significantly lower than the other two proteins; it has been 
reported earlier that P-gp and BCRP were at a much higher 
level than MRP1 in liver tissue or hepatocellular carcinoma 
cell lines.26 Also, the proteins expression in HepG-2 was 
lower than those in the other two cell lines. Meanwhile, the 
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Figure 1 Chromatograms for surrogate peptides. 
Notes: Total ion chromatograms for the developed LC–MS/MS method applied to measure surrogate peptides and their stable isotope-labeled IS peptides in human serum 
albumin (A) and in membrane protein (B).
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; cps, counts per second; LC, liquid 
chromatography; MS, mass spectrometry; IS, internal standards.
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IC
50
 values of the parental HepG-2 cell line of ADM, MX, 
and MTX were also lower than those in the other two cell 
lines (data not shown). 
Induction effect of drug on ABC 
transporter
The target proteins overexpression in resistance cell lines 
was monitored in quadruplicate (Figure 4). It is easy to note 
that the induction effects of the drugs on the protein are rela-
tively stable, and during the process of drug resistance, the 
expression levels of the three proteins increased. However, 
the induction effect of different drugs on proteins is selective. 
When cell lines were induced by ADM, the expression of 
P-gp and BCRP increased rapidly. At the end of the induction, 
in MCF-7, P-gp expression increased by 6.9 times ( Figure 4A), 
while BCRP expression increased by 7.2 times (p); in HepG-
2, P-gp expression increased by 5.7 times (Figure 4A), while 
BCRP expression increased by 5.1 times (p); in SMMC-7721, 
P-gp expression increased by 4.7 times (Figure 4A), while 
BCRP expression increased by 5.0 times (p). However, the 
MRP1 expression increased relatively slowly (in MCF-7: 
2.3 times, in HepG-2: 2.8 times, in SMMC-7721: 2.6 times) 
(g). When cell lines were treated with MX, all three proteins 
expression increased, but the induction degree of MX to MRP1 
was significantly greater than that of ADM (in MCF-7: 4.7 
times, in HepG-2: 7.1 times, in SMMC-7721: 5.9 times) (h), 
which means MX can selectively induce MRP1 to overexpress 
in resistance cells. MTX can also cause ABC transporters 
overexpression, but no obvious selectivity is found.
There have been numerous published studies consistent 
with the results of the induction effect of drugs on ABC 
transporter in this experiment. Meanwhile, studies which 
used other types of cancer cells to establish resistant cell lines 
also match the conclusions of this paper (Table 4).
To study whether the level of target proteins expression 
in all resistant cells is related to its gene, target proteins 
mRNA expression was investigated by RT-PCR. The obser-
vations from different multidrug-resistant cell lines did not 
show the same pattern of protein or mRNA level of target 
proteins expression. Although RT-PCR can provide valuable 
information of protein expression on transcriptional level, it 
often lacks necessary precision and reproducibility for moni-
toring subtle changes. In Figure 4, RT-PCR results showed 
that most of the target mRNA did not change significantly in 
the process of MDR while the corresponding protein amount 
increased gradually.
Meanwhile, the result of the transcript analysis could not 
be used as direct evidence for protein expression. It has been 
Table 2 Intra and interday accuracy and precision for the determination of transporter proteins in human serum albumin (2 mg/mL)
Protein Nominal concentration 0.1 ng/mL (LLOQ) 0.16 ng/mL 4 ng/mL 80 ng/mL
P-gp Mean 0.1056 0.152 3.89 82.33
%Bias 5.6
−5.2 −2.8 2.9
Intraday precision (%CV) 9.8 9.2 2.5 5.3
Interday precision (%CV) 10.2 8.9 2.3 5.7
BCRP Mean 0.1046 0.161 3.881 81.77
%Bias 4.6 0.6
−3 2.2
Intraday precision (%CV) 8.8 8.9 1.5 3.2
Interday precision (%CV) 9.5 9.2 1.8 2.5
MRP1 Mean 0.0955 0.155 3.928 81.63
%Bias
−5.5 −3.1 −1.8 2
Intraday precision (%CV) 9.7 9.3 2.8 2.4
Interday precision (%CV) 12.2 8.9 0.8 2.1
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; LLOQ, lower limit of quantification; 
%CV, percent coefficient of variation.
Figure 2 Digestion efficiency of different ABC transporters in membrane protein 
(each 200 μg). 
Notes: Digestion efficiency of different ABC transporters in membrane protein 
(each 200 μg) after tryptic digestion (1:40) at 37°C for 2, 4, 16, and 24 hours. All 
experiments were performed in triplicate (mean ± SD is given).
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-
related protein 1; BCRP, breast cancer resistance proteins.
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reported that proteins levels were not always in agreement 
with the level of its mRNA. For example, Gomez-Martinez 
et al27 have shown that the changes of P-gp mRNA expres-
sion did not influence P-gp protein activity but did affect 
P-gp mRNA destabilization and P-gp translation inhibi-
tion. Taipalensuu et al28 have pointed out that the transcript 
analysis’ predictive power of protein expression has to be 
investigated on a case-by-case basis. Therefore, the mRNA 
level only gives hints on a general pattern of expression but 
no information on the actual level of protein expression.29
Relationship between ABC transporters expression 
level and type of cell line
The absolute concentration and relative value (protein 
concentration in resistance cell line divided by that in the 
parental cell line) of P-gp, MRP1, and BCRP were detected 
and calculated, and Friedman M test was used to determine 
whether the expression pattern of the proteins was affected 
by the cell type. As is shown in Table 5, there were significant 
differences in the absolute concentration of proteins expres-
sion among different types of cell lines (P<0.05), but no sta-
tistically significant difference in the relative value (P>0.05). 
The result in our experiment shows that during the 
development of drug resistance, the expression level of ABC 
transporters was affected by the cell’s ability to express cor-
responding proteins. The cell type and patch were the most 
important determinant factors of the overexpression level of 
ABC transporters in resistance cell lines, instead of the drug 
(Figure 5). Our conclusion about the pattern of ABC transport-
ers overexpression also conforms to the resistance mechanism 
mentioned above. The reason for the contradictory results in 
other published studies may be the different type of cell lines 
they used causing different levels of ABC transport expres-
sion. For studies which used the same type of cell line but yet 
resulted in contrary conclusions, the reasoning may be that the 
semiquantitative method they used may not have been precise 
enough to observe minor differences caused by the drug. 
Conclusion
In our study, an LC–MS/MS-based targeted proteomics assay 
for the quantification of P-gp, MRP1, and BCRP was devel-
oped by measuring the corresponding surrogate peptides. The 
method was shown to possess sufficient specificity, sensitiv-
ity, accuracy, precision, and stability to measure transporter 
proteins in the drug-resistant cell lines. Using this assay, the 
amounts of target proteins in drug-resistant cells induced 
by different concentrations of ADM, MX, and MTX were 
successfully measured.
The result shows that the induction effects of drugs on pro-
teins are relatively stable and selective. The expression levels of 
P-gp, MRP1, and BCRP in the parental cells of MCF-7, HepG-
2, and SMMC-7721 were different. Also, during the develop-
ment of drug resistance, the cell type and patch were the most 
important determinant factors of the level of ABC transporters 
overexpression, instead of the drug type. This study provides 
a good foundation for understanding the development of drug 
Table 3 Results of stability tests for transporter-specific peptides
Parameter 
protein
Short-term (bench-top) stability (%) 
2 hours at room temperature
Post-preparative (rack) stability (%)
24 hours at 5°C (autosampler)
Digestion stability (%)
16 hours at 37°C
P-gp 97.3–106.6 99.4–107.2 96.7–108.4
MRP1 96.8–103.4 94.7–104.2 94.9–106.2
BCRP 98.1–107.7 93.9–104.6 97.3–104.8
Notes: Results are given as mean values in percentages of the respective initial concentrations. All values were derived from (in each case) three quality control sample sets 
(0.16, 4, and 80 ng/mL) in digested HSA (2 mg/mL).
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; HSA, human serum albumin.
Figure 3 Transporter proteins expression in parental cell lines.
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins.
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Figure 4 Analysis of transporter proteins expression and corresponding genes expression. 
Notes: Analysis of transporter proteins expression induced by drugs (P-gp/ADM, A; P-gp/MX, B; P-gp/MTX, C; MRP1/ADM, G; MRP1/MX, H; MRP1/MTX, I; BCRP/ADM, 
M; BCRP/MX, N; BCRP/MTX, O) and corresponding gene expression (ABCB1/ADM, D; ABCB1/MX, E; ABCB1/MTX, F; ABCC1/ADM, J; ABCC2/MX, K; ABCC2/MTX, 
L; ABCG2/ADM, P; ABCG2/MX, Q; ABCG2/MTX, R) in resistance cell lines. Data are given in mean ± SEM. 
*P<0.01, significant differences between parental cells and drug-resistant cell lines; **P<0.01, significant differences between drug-resistant cell lines treated with the same 
chemotherapeutic drugs.
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; ADM, adriamycin; MX, mitoxantrone; 
MTX, methotrexate; SEM, standard error of mean.
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Table 4 Related reports in published studies which are consistent with our experimental results about the induction effect of drugs 
on ABC transporter
Drug Protein Cell line Method Induction effect
ADM P-gp, MRP1, 
BCRP
MCF-7 RT-PCR Louisa et al7 proved that after pretreatment with doxorubicin, the expression of P-gp, 
MRP1, and BCRP in MCF-7 increased significantly.
P-gp and 
MRP1
HepG-2 Western blot Ye et al14 incubated HepG-2 for 24 hours with ADM and found that the expression of P-gp 
and MRP1 was significantly increased.
P-gp SMMC-7721 Flow cytometry Yan et al15 measured protein expression level with flow cytometry and pointed out that in 
SMMC-7721/ADM, P-gp expression increased.
MX P-gp and 
MRP1
MCF-7 Western blot Morrow et al9 found that P-gp and MRP1 were both increased in MCF-7/MX.
BCRP MCF-7 Western blot Greijer et al13 induced MCF-7 with MX and WB results showed that the expression of 
BCRP increased.
BCRP HepG-2 RT-PCR, 
Western blot, 
flow cytometry
Ren et al12 measured high BCRP expression in HepG-2/MX.
P-gp PBMCs RT-PCR, flow 
cytometry
Yao et al17 proved that the expression of P-gp in the resistant cells was higher. 
MTX MRP1 MCF-7 Western blot Volk et al16 showed that MRP1 expression increased when MCF-7 was induced by MTX.
BCRP HL-60 Flow cytometry Hilovska et al11 proved that BCRP was overexpressed in resistant cells.
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; ADM, adriamycin; MX, mitoxantrone; 
MTX, methotrexate; PBMCs, peripheral blood mononuclear cells; RT-PCR, real-time polymerase chain reaction; WB, Western blot. 
Table 5 P-values of absolute concentration and relative value of ABC transporters overexpression (n=16)
Drug P-gp MRP1 BCRP
Absolute 
concentration
Relative value Absolute  
concentration
Relative 
value
Absolute  
concentration
Relative value
ADM 0.018 0.097 0.039 0.264 0.039 0.717
MX 0.018 0.097 0.039 0.097 0.039 0.264
MTX 0.018 0.097 0.174 0.097 0.039 0.097
Abbreviations: P-gp, permeability glycoprotein; MRP1, multidrug resistance-related protein 1; BCRP, breast cancer resistance proteins; ADM, adriamycin; MX, mitoxantrone; 
MTX, methotrexate. 
Figure 5 The overexpression of ABC transporters in cells and its effect on the development of drug resistance.
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resistance in cell lines and can be used to explain the contradic-
tory results in other published studies. When monitoring the 
expression of drug-resistant proteins, researchers can choose 
to use a quantitative method as an analysis technique to avoid 
the shortcomings of Western blot/RT-PCR.
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